Lyell Immunopharma Ownership | Who Owns Lyell Immunopharma?

Overview Forecast RevenueFinancials Chart

Lyell Immunopharma Ownership Summary

Lyell Immunopharma is owned by 62.57% institutional investors, 14.87% insiders, and 22.56% retail investors. Blackrock is the largest institutional shareholder, holding 5.31% of LYEL shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 1.44% of its assets in Lyell Immunopharma shares.

LYEL Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Lyell Immunopharma	62.57%	14.87%	22.56%
Sector	Healthcare Stocks	492.67%	11.09%	-403.76%
Industry	Biotech Stocks	295.31%	11.22%	-206.53%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	13.50M	5.31%	$19.57M
Vanguard group	779.00K	5.27%	$12.65M
Wuxi apptec	7.68M	3.02%	$11.14M
Alphabet	293.26K	1.98%	$4.76M
Blackrock funding, inc. /de	176.81K	1.20%	$2.87M
Geode capital management	130.26K	0.88%	$2.12M
Arch venture management	1.82M	0.62%	$16.11M
Charles schwab investment management	79.51K	0.54%	$1.29M
Renaissance	63.99K	0.43%	$1.04M
D. e. shaw	966.26K	0.38%	$618.41K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Wuxi apptec	7.68M	47.74%	$11.14M
Arch venture management	1.82M	5.39%	$16.11M
Takeda pharmaceutical	41.16K	1.86%	$363.91K
Decheng capital	595.47K	1.33%	$5.26M
Alphabet	293.26K	0.20%	$4.76M
Rbf capital	100.00K	0.04%	$884.00K
Clarius group	19.96K	0.02%	$324.12K
Orbimed advisors	51.73K	0.01%	$457.27K
China universal asset management	3.37K	0.00%	$54.68K
Susquehanna fundamental investments	128.20K	0.00%	$185.89K

Top Buyers

Holder	Shares	% Assets	Change
Arch venture management	1.82M	5.39%	1.82M
D. e. shaw	966.26K	0.00%	493.64K
Wellington management group llp	367.68K	0.00%	367.68K
Vanguard group	779.00K	0.00%	336.38K
Millennium management	957.51K	0.00%	247.44K

Top Sellers

Holder	Shares	% Assets	Change
Foresite capital management iv	-	-	-16.01M
Decheng capital	595.47K	1.33%	-11.31M
Foresite capital management v	-	-	-8.13M
Venbio partners	-	-	-7.10M
Price t rowe associates inc /md/	-	-	-6.48M

New Positions

Holder	Shares	% Assets	Change	Value
Arch venture management	1.82M	5.39%	1.82M	$16.11M
Wellington management group llp	367.68K	0.00%	367.68K	$533.13K
Rbf capital	100.00K	0.04%	100.00K	$884.00K
Orbimed advisors	51.73K	0.01%	51.73K	$457.27K
Walleye capital	29.23K	0.00%	29.23K	$258.39K

Sold Out

Holder	Change
Eversource wealth advisors	-1.00
Pnc financial services group	-4.00
True wealth design	-23.00
Nelson, van denburg & campbell wealth management group	-34.00
Rothschild investment	-50.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	68	-39.82%	9,256,423	-93.92%	62	939.01%	12	-68.42%	55	52.78%
Mar 31, 2025	112	8.74%	152,309,719	1.35%	51	1.50%	38	-26.92%	37	48.00%
Dec 31, 2024	97	-17.09%	146,305,210	13.92%	57	2.27%	47	-6.00%	24	-22.58%
Sep 30, 2024	117	0.86%	128,424,945	-3.67%	50	1.82%	51	4.08%	31	-27.91%
Jun 30, 2024	116	-5.69%	133,324,052	0.44%	52	1.91%	49	-14.04%	43	-2.27%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	276.12K	1.44%	-6.10K
iShares Russell 2000 ETF	4.13M	1.39%	-
T. Rowe Price Health Sciences	212.18K	1.10%	-2.38K
Biotech Growth Ord	2.88M	0.99%	-
Vanguard Small Cap Index	2.24M	0.87%	5.37K
iShares Russell 2000 Value ETF	1.47M	0.49%	-
Vanguard Small Cap Growth Index Inv	1.25M	0.49%	-5.54K
Vanguard Institutional Extnd Mkt Idx Tr	91.69K	0.48%	-37.12K
Fidelity Small Cap Index	1.63M	0.44%	-
State St Russell Sm/Mid Cp® Indx NL Cl C	1.18M	0.40%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Nov 10, 2025	Seely Lynn	President and CEO	Sell	$6.64K
Nov 10, 2025	Bulis Veronica Sanchez	VP, Corporate Controller	Sell	$3.85K
Nov 10, 2025	Lee Gary K.	Chief Scientific Officer	Sell	$2.23K
Nov 10, 2025	Hill Stephen J.	Chief Operating Officer	Sell	$1.53K
Aug 21, 2025	Seely Lynn	President and CEO	Sell	$76.52K

Insider Transactions Trends

Date	Buy	Sell
2025 Q4	-	4
2025 Q3	-	12
2025 Q2	-	-
2025 Q1	5	-
2024 Q4	-	-

LYEL Ownership FAQ

Who Owns Lyell Immunopharma?

Lyell Immunopharma shareholders are primarily institutional investors at 62.57%, followed by 14.87% insiders and 22.56% retail investors. The average institutional ownership in Lyell Immunopharma's industry, Biotech Stocks , is 295.31%, which Lyell Immunopharma falls below.

Who owns the most shares of Lyell Immunopharma?

Lyell Immunopharma’s largest shareholders are Blackrock (13.5M shares, 5.31%), Vanguard group (779K shares, 5.27%), and Wuxi apptec (7.68M shares, 3.02%). Together, they hold 13.60% of Lyell Immunopharma’s total shares outstanding.

Does Blackrock own Lyell Immunopharma?

Yes, BlackRock owns 5.31% of Lyell Immunopharma, totaling 13.5M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 19.57M$. In the last quarter, BlackRock decreased its holdings by -397K shares, a -2.86% change.

Who is Lyell Immunopharma’s biggest shareholder by percentage of total assets invested?

Wuxi apptec is Lyell Immunopharma’s biggest shareholder by percentage of total assets invested, with 47.74% of its assets in 7.68M Lyell Immunopharma shares, valued at 11.14M$.

Who is the top mutual fund holder of Lyell Immunopharma shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Lyell Immunopharma shares, with 1.44% of its total shares outstanding invested in 276.12K Lyell Immunopharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools